Skip to main content Accessibility help
×
Home
Hostname: page-component-6f6fcd54b-sdp72 Total loading time: 0.211 Render date: 2021-05-11T08:33:15.170Z Has data issue: true Feature Flags: {}

Article contents

5 Clinical Evaluation of the Abuse Potential of Buprenorphine/Samidorphan Combination

Published online by Cambridge University Press:  12 March 2019

Andrew J. Cutler
Affiliation:
Meridien Research, Bradenton, FL
Sanjay J. Mathew
Affiliation:
Psychiatrist, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX
Michael E. DeBakey
Affiliation:
Veterans Affairs Medical Center, Houston, TX
Beatrice Setnik
Affiliation:
Vice President Scientific & Clinical Strategy, Early Phase, Department of Pharmacology & Toxicology, Syneos Health, Raleigh, NC; University of Toronto, Toronto, ON, Canada
Narinder Nangia
Affiliation:
Senior Director, Biostatistics, Biostatistics, Alkermes, Inc., Waltham, MA
Arielle D. Stanford
Affiliation:
Medical Director, Clinical Research, Clinical Research, Alkermes, Inc., Waltham, MA
Sanjeev Pathak
Affiliation:
VP, Clinical Research Psychiatry, Clinical Research, Alkermes, Inc., Waltham, MA
Rights & Permissions[Opens in a new window]

Abstract

Introduction

Buprenorphine (BUP)/samidorphan (SAM) combination is an opioid system modulator being investigated as an adjunctive treatment for major depressive disorder (MDD). BUP/SAM is a fixed-dose combination of BUP, a partial µ-opioid receptor agonist and κ-opioid receptor antagonist, and SAM, a µ-opioid receptor antagonist added to address the abuse and dependence potential of BUP.1,2

Study Objective

We assessed the effects of SAM on the abuse potential of BUP in the BUP/SAM combination in two ways: (1) a human abuse potential (HAP) study in volunteers; and (2) an evaluation of the clinical experience across studies of patients with MDD.

Methods

Study 212 (ClinicalTrials.gov ID: NCT02413281) was a HAP study in nondependent, recreational, adult opioid users. Following a qualification period, participants were randomized to 6 treatments in a blinded, crossover design: placebo (PBO), BUP/SAM at the target therapeutic dose (BUP/SAM 2mg/2mg), at 8mg/8mg and 16mg/16mg , and BUP alone (8mg and 16mg). The primary endpoint was maximum effect (Emax) for “At The Moment” Drug Liking Visual Analog Scale (VAS).

The clinical program for BUP/SAM included 4 PBO-controlled studies of patients with MDD (n=961). Pooled safety data were evaluated for adverse events (AEs) that may be associated with abuse, dependence, or withdrawal, as well as for objective signs of withdrawal with the Clinical Opioid Withdrawal Scale (COWS).

Results

In Study 212 (n=38), Emax Drug Liking VAS scores for the BUP/SAM 2mg/2mg dose were similar to those for PBO (median within-subject difference [90% CI]: 2.5 [0.0–9.0]). Emax Drug Liking VAS scores for all BUP/SAM dose groups, including supratherapeutic doses, were significantly lower than those observed for either of the BUP doses. The supratherapeutic doses of BUP/SAM (8mg/8mg and 16mg/16mg) had higher Emax Drug Liking VAS scores than PBO, but the differences were small.

In the MDD controlled studies, the incidence of euphoria-related AEs was low for BUP/SAM 2mg/2mg and PBO (1.6% vs 0.2%, respectively) and there was no evidence of abuse or dependence behavior. Euphoria-related events typically occurred with treatment initiation and resolved with continued treatment. There was minimal evidence of withdrawal by reported AEs or COWS assessment.

Conclusions

These findings indicate that SAM mitigates the abuse potential of BUP in the BUP/SAM combination.

Funding Acknowledgements: Alkermes, Inc.

Type
Abstracts
Copyright
© Cambridge University Press 2019 
You have Access

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

5 Clinical Evaluation of the Abuse Potential of Buprenorphine/Samidorphan Combination
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

5 Clinical Evaluation of the Abuse Potential of Buprenorphine/Samidorphan Combination
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

5 Clinical Evaluation of the Abuse Potential of Buprenorphine/Samidorphan Combination
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *